Last reviewed · How we verify
Cebranopadol 600 µg
Cebranopadol is a kappa opioid receptor agonist and mu opioid receptor agonist.
Cebranopadol is a kappa opioid receptor agonist and mu opioid receptor agonist. Used for Chronic pain.
At a glance
| Generic name | Cebranopadol 600 µg |
|---|---|
| Also known as | Treatment Phase, Experimental |
| Sponsor | Tris Pharma, Inc. |
| Drug class | opioid receptor agonist |
| Target | kappa opioid receptor, mu opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain management |
| Phase | Phase 2 |
Mechanism of action
Cebranopadol's dual action on kappa and mu opioid receptors contributes to its analgesic effects. This mechanism allows for a more balanced approach to pain management, potentially reducing the risk of opioid-related side effects.
Approved indications
- Chronic pain
Common side effects
- Nausea
- Dizziness
- Headache
Key clinical trials
- Cebranopadol Effects on Ventilatory Drive, Central Nervous System (CNS) and Pain. (PHASE1)
- Assessment of Abuse Potential of Cebranopadol in Humans (PHASE1)
- CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer (PHASE3)
- CORAL XT - Open-label Extension Trial of the CORAL Trial (PHASE3)
- Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cebranopadol 600 µg CI brief — competitive landscape report
- Cebranopadol 600 µg updates RSS · CI watch RSS
- Tris Pharma, Inc. portfolio CI